Key Highlights

  • Ping An Biomedical (NASDAQ:PASW) traded at USD 4.04, down 18.55% intraday on November 4, 2026, on Volume of about 15,960 shares, a very thin tape.
  • A 1-for-40 share consolidation took effect on October 23, 2026, cutting roughly 125.1 million pre-split shares to about 3.1 million before rounding.
  • A Form F-3 shelf filed on October 23, 2026 covers up to USD 300 million of securities, while one Shareholder holds about 91.56% of voting power.
  • The company signed a letter of intent for three tumor-related patents valued at USD 2.0 million to USD 2.5 million, a deal it says adds little near-term revenue.

What Moved Ping An Biomedical During Trading (down USD 0.92, 18.55%)

Ping An Biomedical (NASDAQ:PASW) was down 18.55%, or USD 0.92, at USD 4.04 in intraday trading on November 4, 2026, which implies a prior close of about USD 4.96 (calculated). No company announcement dated November 2 to November 4, 2026 was identified after searching company releases and filing lists, so the decline is best described as trading driven. Published market data showed about 15,960 shares changing hands, and relative volume of 0.18 means activity was well below normal. On a Market Value near USD 11.4 million, a handful of orders can shift the quote by a double-digit move.

The Reverse Split, Shelf and Patent Letter of Intent

Per the company release, a 1-for-40 consolidation of Class A and Class B shares took effect on October 23, 2026. Before it, there were 112,867,000 Class A and 12,250,000 Class B shares, and about 2,821,675 Class A and 306,250 Class B were expected afterward, subject to rounding. A reverse split raises the quoted price by combining shares but does not change the value of a holder's stake, and many such stocks drift lower afterward when Supply returns. The same day the company filed a Form F-3 for up to USD 300 million of shares, preferred shares, debt, warrants and units. It also reported a letter of intent for three tumor-related patents at USD 2.0 million to USD 2.5 million, and it expects little near-term Revenue from them.

Business Background, Listing Status and Risks

The company was formerly Majestic Ideal Holdings, completed its IPO in July 2025 and was renamed in September 2025. Its filings describe an apparel supply chain Business serving China, Hong Kong, Cambodia and Europe. Fiscal 2025 revenue was RMB 34.15 million, down 61.03% from RMB 87.62 million, with a loss of RMB 12.83 million. Nasdaq sent a minimum bid price deficiency letter on November 24, 2025, with a first compliance period to May 25, 2026. Any shelf takedown would dilute holders, since issuing new shares spreads Earnings and ownership across a larger count. Small trade counts, wide spreads and reversible quoted moves are normal here, and the move says nothing about direction ahead.

Where Things Stand

Ping An Biomedical (NASDAQ:PASW) is down 18.55% on November 4, 2026 without any company announcement dated November 2 to November 4, 2026 being identified. The move looks trading driven, following a reverse split on October 23, a USD 300 million shelf filing and a patent letter of intent that the company says adds little near-term revenue. With a market value near USD 11.4 million and light volume, price changes can be large and can reverse quickly. Investors should treat the quote as unreliable for judging value.